ALLogeneic heart STem cells to achieve myocardial regeneration (ALLSTAR) trial: Rationale and design

Cell Transplantation

Volumn 26, Issue 2, 2017, Pages 205-214

  Chakravarty, Tarun ^a   Makkar, Raj R ^a   Ascheim, Deborah D ^b   Traverse, Jay H ^c   Schatz, Richard ^d   Demaria, Anthony ^e   Francis, Gary S ^c   Povsic, Thomas J ^f   Smith, Rachel R ^b   Lima, Joao A ^g   Pogoda, Janice M ^h   Marbán, Linda ^b   Henry, Timothy D ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Capricor Therapeutics   (United States)

^c MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^d Pediatric/Adolescent Sports Medicine Program   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g JOHNS HOPKINS HOSPITAL   (United States)

^h Department of Urology   (United States)

Author keywords

Myocardial infarction (MI); Regenerative medicine; ST elevation MI; Stem cells; Trial design

Indexed keywords

PLACEBO;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGENERATIVE MEDICINE; THERAPY EFFECT; AUTOTRANSPLANTATION; CARDIAC MUSCLE CELL; CELL CULTURE; CLINICAL TRIAL; CYTOLOGY; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; METABOLISM; PHYSIOLOGY; PROCEDURES; STEM CELL; STEM CELL TRANSPLANTATION;

CELLS, CULTURED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION, AUTOLOGOUS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85012202217     PISSN: 09636897     EISSN: 15553892     Source Type: Journal    
DOI: 10.3727/096368916X692933     Document Type: Article

References (20)

1. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012;379 (9819):895-904.
2. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, Marbán L, Mendizabal A, Cingolani E, Johnston PV, Gerstenblith G, Schuleri KH, Lardo AC, Marbán E. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphereDerived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110-22.
3. Zhuo Y, Li SH, Chen MS, Wu J, Kinkaid HY, Fazel S, Weisel RD, Li RK. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: Combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg. 2010;139(5):1286-94, 1294.e1-2.
4. Kinkaid HY, Huang XP, Li RK, Weisel RD. What’s new in cardiac cell therapy? Allogeneic bone marrow stromal cells as “universal donor cells”. J Card Surg. 2010;25(3):359-66
5. Perin EC, Silva GV, Henry TD, Cabreira-Hansen MG, Moore WH, Coulter SA, Herlihy JP, Fernandes MR, Cheong BY, Flamm SD, Traverse JH, Zheng Y, Smith D, Shaw S, Westbrook L, Olson R, Patel D, Gahremanpour A, Canales J, Vaughn WK, Willerson JT. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J. 2011;161(6):1078-87.e3.
6. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial. JAMA 2012;307(16):1717-26.
7. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr., Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277-86.
8. Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang P, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or non-ischemic heart failure. Circ Res. 2015;117(6):576-84.
9. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012;308(22):2369-79.
10. Ascheim DD, Gelijns AC, Goldstein D, Moye LA, Smedira N, Lee S, Klodell CT, Szady A, Parides MK, Jeffries NO, Skerrett D, Taylor DA, Rame JE, Milano C, Rogers JG, Lynch J, Dewey T, Eichhorn E, Sun B, Feldman D, Simari R, O’Gara PT, Taddei-Peters WC, Miller MA, Naka Y, Bagiella E, Rose EA, Woo YJ. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 2014;129(22):2287-96.
11. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, Galang G, Zhang Y, Schoenhoff F, Van Eyk J, Marbán L, Marbán E. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2012;125(1):100-12.
12. Tseliou E, Pollan S, Malliaras K, Terrovitis J, Sun B, Galang G, Marbán L, Luthringer D, Marbán E. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol. 2013;61(10):1108-19.
13. Malliaras K, Smith RR, Kanazawa H, Yee K, Seinfeld J, Tseliou E, Dawkins JF, Kreke M, Cheng K, Luthringer D, Ho CS, Blusztajn A, Valle I, Chowdhury S, Makkar RR, Dharmakumar R, Li D, Marbán L, Marbán E. Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation 2013;128(25):2764-75.
14. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Giacomello A, Abraham MR, Marbán E. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115(7):896-908.
15. Wassmer, G. On sample size determination in multi-armed confirmatory adaptive designs. J Biopharm Stat. 2011;21(4): 802-17.
16. Jeong H, Yim HW, Cho Y, Park HJ, Jeong S, Kim HB, Hong W, Kim H. The effect of rigorous study design in the research of autologous bone marrow-derived mononuclear cell transfer in patients with acute myocardial infarction. Stem Cell Res Ther. 2013;4(4):82.
17. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol. 2002;39(9):1414-21.
18. Desch S, Eitel I, de Waha S, Fuernau G, Lurz P, Guttberlet M, Schuler G, Thiele H. Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction. Trials 2011;12:204.
19. Larose E, Rodés-Cabau J, Pibarot P, Rinfret S, Proulx G, Nguyen CM, Déry JP, Gleeton O, Roy L, Noël B, Barbeau G, Rouleau J, Boudreault JR, Amyot M, De Larochellière R, Bertrand OF. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol. 2010;55(22):2459-69.
20. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, Carr JC, Holly TA, Lloyd-Jones D, Klocke FJ, Bonow RO. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: Prospective cohort study. Heart 2008;94(6):730-6.